JP2014169326A5 - - Google Patents

Download PDF

Info

Publication number
JP2014169326A5
JP2014169326A5 JP2014121152A JP2014121152A JP2014169326A5 JP 2014169326 A5 JP2014169326 A5 JP 2014169326A5 JP 2014121152 A JP2014121152 A JP 2014121152A JP 2014121152 A JP2014121152 A JP 2014121152A JP 2014169326 A5 JP2014169326 A5 JP 2014169326A5
Authority
JP
Japan
Prior art keywords
antibody
ngf
pharmaceutical composition
use according
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014121152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014169326A (ja
Filing date
Publication date
Priority claimed from US12/576,522 external-priority patent/US9260514B2/en
Application filed filed Critical
Publication of JP2014169326A publication Critical patent/JP2014169326A/ja
Publication of JP2014169326A5 publication Critical patent/JP2014169326A5/ja
Ceased legal-status Critical Current

Links

JP2014121152A 2009-10-09 2014-06-12 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体 Ceased JP2014169326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/576,522 2009-10-09
US12/576,522 US9260514B2 (en) 2003-07-15 2009-10-09 Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012533344A Division JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206106A Division JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Publications (2)

Publication Number Publication Date
JP2014169326A JP2014169326A (ja) 2014-09-18
JP2014169326A5 true JP2014169326A5 (enExample) 2015-06-18

Family

ID=43466840

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012533344A Pending JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
JP2014121152A Ceased JP2014169326A (ja) 2009-10-09 2014-06-12 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
JP2016206106A Withdrawn JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012533344A Pending JP2013507385A (ja) 2009-10-09 2010-10-08 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206106A Withdrawn JP2017014286A (ja) 2009-10-09 2016-10-20 選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体

Country Status (28)

Country Link
US (1) US9260514B2 (enExample)
EP (2) EP2485760B1 (enExample)
JP (3) JP2013507385A (enExample)
KR (1) KR101528393B1 (enExample)
CN (1) CN102762228A (enExample)
AR (1) AR078569A1 (enExample)
AU (2) AU2010308418A1 (enExample)
BR (1) BR112012008282A2 (enExample)
CA (1) CA2775924A1 (enExample)
CL (1) CL2012000881A1 (enExample)
CO (1) CO6541558A2 (enExample)
CR (1) CR20120198A (enExample)
EA (1) EA201290189A1 (enExample)
IL (1) IL218885A0 (enExample)
MA (1) MA33724B1 (enExample)
ME (1) ME00226B (enExample)
MT (1) MTP4289B (enExample)
MX (1) MX343748B (enExample)
MY (1) MY172283A (enExample)
NZ (2) NZ625391A (enExample)
PE (1) PE20121028A1 (enExample)
PH (1) PH12012500668A1 (enExample)
SG (1) SG10201603945RA (enExample)
TN (1) TN2012000136A1 (enExample)
TW (1) TW201125581A (enExample)
UA (1) UA102775C2 (enExample)
WO (1) WO2011049758A1 (enExample)
ZA (1) ZA201203135B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CN102459337B (zh) 2009-05-04 2015-05-20 雅培研究有限责任公司 具有增强的体内稳定性的抗神经生长因子(ngf)抗体
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ngf 조성물 및 그의 용도
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR102362002B1 (ko) * 2013-11-29 2022-02-10 제넨테크, 인크. 항체 선택 장치 및 방법
JP2018516112A (ja) 2015-04-17 2018-06-21 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 異方性をもつ生物学的組織の検出
AU2017366870B2 (en) 2016-11-29 2024-09-19 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction
WO2019178364A2 (en) * 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3833687A1 (en) 2018-08-10 2021-06-16 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113549150A (zh) * 2020-04-26 2021-10-26 三生国健药业(上海)股份有限公司 结合人ngf的抗体、其制备方法和用途
EP4157881A4 (en) * 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
IT202000020287A1 (it) * 2020-08-20 2022-02-20 Colosseum Combinatorial Chemistry Centre For Tech Societa A Responsabilita Limitata In Forma Abbrevi Peptide per applicazioni terapeutiche in campo dermatologico
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023139542A1 (en) * 2022-01-21 2023-07-27 Institut Pasteur De Montevideo Active immunization for reducing osteoarthritic, neuropathic, and cancer pain
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US913242A (en) 1905-08-29 1909-02-23 Electrelle Company Automatic music-playing attachment for pianos.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JP2969647B2 (ja) 1988-09-14 1999-11-02 東ソー株式会社 モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
ES2109225T3 (es) 1989-08-28 1998-01-16 Takeda Chemical Industries Ltd Anticuerpos, su produccion y uso.
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JP3232415B2 (ja) 1990-08-29 2001-11-26 武田薬品工業株式会社 モノクローナル抗体,その製造法および用途
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP3519096B2 (ja) 1992-07-02 2004-04-12 武田薬品工業株式会社 モノクローナル抗体、ハイブリドーマおよびそれらの用途
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2796140A1 (en) 1999-03-25 2000-09-28 Jochen Salfeld Human antibodies that bind human il-12 and methods for producing
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CA2975521A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
KR20050036852A (ko) 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-hla-dr 항체
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经系统学公司 抗ngf抗体及其使用方法
CN1849138B (zh) 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
KR100894191B1 (ko) * 2003-07-15 2009-04-22 암젠 인코포레이티드 선택적인 ngf 경로 저해제로서의 인체 항-ngf 중화 항체 및 이 항체를 포함하는 약학적 조성물
EP1846451B1 (en) 2005-01-24 2013-05-15 Medimmune Limited Human antibodies against human ngf
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Similar Documents

Publication Publication Date Title
JP2014169326A5 (enExample)
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2014502955A5 (enExample)
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
AR088458A1 (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
HRP20210250T1 (hr) Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
UA113626C2 (xx) Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
JP2016502515A5 (enExample)
RU2012156938A (ru) Антитела против gdf8 человека
RU2017119647A (ru) Способ лечения болезней глаз
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
RU2012122162A (ru) Гликолизированная форма аналога антигенного glp-1
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
JP2015521607A5 (enExample)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2013538796A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2020510039A5 (enExample)
JP2013533268A5 (enExample)
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
JP2018529661A5 (enExample)
JP2015510882A5 (enExample)
IL278717B1 (en) Starting dose of pth conjugates
JP2019533682A5 (enExample)